Parkinson’s meds may interact through gut bacteria, study finds

For decades, doctors treating Parkinson's disease have relied on a familiar combination: levodopa, the drug that replenishes the brain's depleted dopamine supply, paired with a class of medications designed to make levodopa work better. The logic was straightforward. Now a study published in Nature Microbiology is complicating that picture in a way nobody had quite anticipated — by pointing to the gut.

Levodopa works because the brain can convert it into dopamine, the signaling molecule that Parkinson's progressively destroys. The disease itself is defined by the loss of the brain cells that produce dopamine, and without it, the nervous system's ability to coordinate movement breaks down. Levodopa is taken by mouth, absorbed through the digestive tract, and must travel to the brain to do its job. That journey, it turns out, is more treacherous than previously understood.

The drugs paired with levodopa are called catechol-O-methyltransferase inhibitors, or COMT inhibitors. Their purpose is to block enzymes outside the brain that would otherwise degrade levodopa before it arrives. In theory, more levodopa survives the trip; in practice, the combination has been standard care for years. But the new research, funded by the National Institutes of Health, suggests the COMT inhibitors may be quietly undermining the very drug they're meant to protect.

The mechanism runs through the microbiome. The human gut is home to billions of bacteria, each carrying their own enzymatic machinery — machinery that standard drug-interaction testing has largely ignored. Researchers have historically focused on how two drugs affect human enzymes, particularly in the liver. The gut's microbial population rarely enters the calculation. This study argues it should.

What the researchers found, through a series of laboratory experiments, is that COMT inhibitors have a selective antibacterial effect. They suppress certain bacterial populations in the gut. When those populations shrink, other bacteria move in to fill the vacancy — and among the opportunistic colonizers is a group called Enterococcus. That matters because Enterococcus bacteria produce an enzyme capable of breaking down levodopa directly in the intestines, before it ever reaches the bloodstream, let alone the brain.

The chain of events, then, looks something like this: a patient takes levodopa alongside a COMT inhibitor to improve the drug's effectiveness; the COMT inhibitor reshapes the gut's bacterial landscape; Enterococcus expands; and those bacteria degrade a portion of the levodopa in the gut, potentially leaving less of the drug available to reach the brain. The medication meant to boost levodopa's efficacy may, through this indirect route, be blunting it.

Andrew Albert Verdegaal, a co-author of the study and a researcher at Yale University, framed the finding as a window into a broader problem. Most Parkinson's patients require multiple medications simultaneously, and Parkinson's is far from the only condition where co-prescription is the norm. The interaction identified here — one drug reshaping the microbial environment in a way that affects a second drug — could be operating in other disease contexts entirely, largely undetected because no one has been looking for it.

"This drug is a way for the body to externally receive dopamine, but it has to get into the brain to have an effect," Verdegaal noted, underscoring what's at stake when any part of that delivery chain is disrupted.

The study, published under the title "A drug–microbiome–drug interaction impacts co-prescribed medications for Parkinson's disease," does not overturn current treatment protocols. It does not tell clinicians to stop prescribing COMT inhibitors. What it does is open a door that pharmacology has kept mostly closed: the possibility that the microbiome is an active participant in drug interactions, not a passive bystander. For the roughly ten million people worldwide living with Parkinson's, and for the researchers trying to optimize their treatment, that door is worth walking through.